ACT11 is under clinical development by Xequel Bio and currently in Phase I for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase I drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACT11’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ACT11 overview

aCT11 (alphaCT11) is under development for the treatment of ischemia and radiation injury (ocular injury induced by chemical warfare agents), Dry eye disease and thermal burn injury (CRBI). AlphaCT11 is developed from the technology based on connexin-based peptides (alpha-Connexin Carboxyl-Terminal or aCT peptides). It is administered into eye as drops.

Xequel Bio overview

Xequel Bio is a biopharmaceutical company that discovers and develops therapies for inflammation and injury based medical conditions. The company markets new therapeutic products that enable physicians to treat unmet medical need. It offers therapeutic approach, which aims to address the disorders by concentrating on mitigating excessive inflammation, calming the inflamed tissue, and rebooting the body’s normal injury response mechanism to allow the healing process to become inhabited. Xequel Bio offers topical granexin gel, which stabilizes gap junctions and tightens junctions of endothelial cells during the wound healing process. The company conducts preclinical programs in the fields such as ophthalmology, organ preservation and oncology. Xequel Bio is headquartered in Mount Pleasant, South Carolina, the US.

For a complete picture of ACT11’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.